Cardiovascular Protective Effect of Spironolactone in Hemodialysis

Status:

UNKNOWN

Cardiovascular Protective Effect of Spironolactone in Hemodialysis

Lead Sponsor:

Universidad de los Andes, Chile

Conditions:

Hemodialysis

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.

Detailed Description

Cardiovascular complications are common in dialysis patients and comprise up to 50% of deaths in end-stage renal disease population. Hypertension and left ventricle hypertrophy occur in more than 70% ...

Eligibility Criteria

Inclusion

chronic hemodialysys (\> 3 months) anuria (diuresis \<200 mL/day) -

Exclusion

Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists Cancer
\-

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00277693

Last Update

January 16 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)